German End-Of-Year Figures Highlight Potential Danger To Pharma R&D
This article was originally published in The Pink Sheet Daily
Executive Summary
The German pharmaceutical market has dealt impressively with the government’s cost-cutting measures, but they are beginning to take their toll on R&D and innovation, industry maintains.
You may also be interested in...
German Austerity Measures Continue As Firms Dispute How Much Has Already Been Saved
Despite overall economic growth, the German health ministry refuses to lift the pharmaceutical price freeze or obligatory rebate to health insurers, saying industry is coping well with them; firms say they have already sacrificed more than had initially been asked.
German Pricing Plan Avoids Terrible Twos, But More Growing Pains Ahead
In the two years since Germany’s reimbursement process for new drugs turned Europe’s largest market into one of the toughest, the impact on pricing hasn’t been as bad as many expected. But there’s more to come, with several on-market categories slated for retrospective review, and even mandatory rebates could follow.
Benlysta And Fampyra Fail to Make Headway As IQWiG Tightens Comparator Screw
Germany’s health technology evaluator’s rejection of GSK’s Benlysta and Biogen Idec’s Fampyra could force companies to design separate trials for authorization and HTA assessment.